Back to Search
Start Over
Long-term control of leptomeningeal disease after radiation therapy and nivolumab in a metastatic melanoma patient
- Source :
- Immunotherapy
- Publication Year :
- 2020
-
Abstract
- Background: Leptomeningeal disease (LMD) from melanoma is rapidly fatal with median overall survival between 6.9 weeks and 3.5 months. It is not known whether immune checkpoint inhibitors have a role in treating LMD. Case presentation: We report a 33-year-old male patient who developed LMD from a BRAF V600E-mutated melanoma brain metastasis, despite prior treatment with surgical resection, radiotherapy and dabrafenib/trametinib. He underwent whole brain radiotherapy with stereotactic radiotherapy to the lumbosacral spine, and was started on nivolumab, which led to prolonged remission lasting 2 years and 3 months, before disease progression and death. Conclusion: This is the first case report to highlight a potential long-term efficacy of radiotherapy and anti-PD-1 immunotherapy, in treating LMD from metastatic melanoma that is resistant to targeted therapy.
- Subjects :
- 0301 basic medicine
Oncology
Adult
Male
Proto-Oncogene Proteins B-raf
medicine.medical_specialty
medicine.medical_treatment
Immunology
Programmed Cell Death 1 Receptor
Case Report
Spinal Cord Diseases
Targeted therapy
03 medical and health sciences
0302 clinical medicine
Antineoplastic Agents, Immunological
Fatal Outcome
Meninges
Internal medicine
medicine
Immunology and Allergy
Humans
Melanoma
Trametinib
business.industry
Brain Neoplasms
Remission Induction
Dabrafenib
Immunotherapy
Radioimmunotherapy
medicine.disease
Radiation therapy
030104 developmental biology
Nivolumab
030220 oncology & carcinogenesis
Mutation
business
medicine.drug
Brain metastasis
Subjects
Details
- ISSN :
- 17507448
- Volume :
- 12
- Issue :
- 11
- Database :
- OpenAIRE
- Journal :
- Immunotherapy
- Accession number :
- edsair.doi.dedup.....4921fe70723e90f7fbca48c939642676